- Home
- ASND vs ALLY Comparison
ASND vs ALLY Comparison
Compare ASND & ALLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASND
- ALLY
- Stock Information
- Founded
- ASND 2006
- ALLY 1919
- Country
- ASND Denmark
- ALLY United States
- Employees
- ASND N/A
- ALLY N/A
- Industry
- ASND Biotechnology: Pharmaceutical Preparations
- ALLY Major Banks
- Sector
- ASND Health Care
- ALLY Finance
- Exchange
- ASND Nasdaq
- ALLY Nasdaq
- Market Cap
- ASND 9.8B
- ALLY 11.3B
- IPO Year
- ASND 2015
- ALLY 2014
- Fundamental
- Price
- ASND $176.90
- ALLY $36.95
- Analyst Decision
- ASND Strong Buy
- ALLY Buy
- Analyst Count
- ASND 16
- ALLY 19
- Target Price
- ASND $218.19
- ALLY $43.19
- AVG Volume (30 Days)
- ASND 411.5K
- ALLY 4.6M
- Earning Date
- ASND 05-01-2025
- ALLY 07-18-2025
- Dividend Yield
- ASND N/A
- ALLY 3.24%
- EPS Growth
- ASND N/A
- ALLY N/A
- EPS
- ASND N/A
- ALLY 0.61
- Revenue
- ASND $398,509,511.00
- ALLY $6,658,000,000.00
- Revenue This Year
- ASND $75.05
- ALLY $20.15
- Revenue Next Year
- ASND $78.14
- ALLY $14.71
- P/E Ratio
- ASND N/A
- ALLY $60.50
- Revenue Growth
- ASND 12.06
- ALLY N/A
- 52 Week Low
- ASND $111.09
- ALLY $29.52
- 52 Week High
- ASND $183.00
- ALLY $45.46
- Technical
- Relative Strength Index (RSI)
- ASND 60.02
- ALLY 59.20
- Support Level
- ASND $169.65
- ALLY $35.94
- Resistance Level
- ASND $178.62
- ALLY $38.05
- Average True Range (ATR)
- ASND 6.77
- ALLY 0.76
- MACD
- ASND 0.03
- ALLY 0.03
- Stochastic Oscillator
- ASND 82.61
- ALLY 70.53
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.